Nucleome Therapeutics, a UK biotech using spatial genomics to discover precision medicines for complex diseases, has appointed Mark Bodmer (pictured, above) as chief executive.
Dr Bodmer joins from Evelo Biosciences (OTCMKTS: EVLO), where since 2016 he served as chief scientific officer and president of R&D.
Previously, he held senior pharma and biotech roles including vice president of new medicines therapeutics at UCB (Euronext: UCB), senior vice president of immune-inflammation at GSK (LSE: GSK), and chief executive of Hexagen (STO: HEXA-B), Lorantis and Biotica.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze